Mr. Wang Jia is a Practice Expert of the Development Cooperation Department at Peking University Institute for Global Health and Development, Assistant Director of the Medical Management and Evaluation Research Department at the China Health Economics Research Center of Peking University, Co-Founder of the Global Health Synthetic Biology Consortium, Chairman of Langrun Liren, an investor in synthetic biology, and an alumnus of the International MBA program at BiMBA Business School of the National School of Development at Peking University.

With ten years of experience in the medical industry and another ten years in venture capital, Mr. Wang Jia first worked as a surgeon for several years before joining Johnson & Johnson, the world's largest medical enterprise, in a management role. He later entered the investment field, focusing on venture capital in the healthcare industry. Many cases he led in investment have been selected into the Top 10 list of ChinaVenture and the Fortune Influence List.

Recent Professional Contributions:

In 2022, based on a review of 300 enterprises from in-depth research, he formulated Methodology for Assessing Enterprise Founders and Organizations and delivered a special lecture on this topic to more than 1,400 investors at the Zero2IPO Investment Training Institute.

In 2024, he edited and completed China's first Blue Book on Synthetic Biology Industry Practices, which was officially released at Peking University. He also received special interviews on synthetic biology from authoritative institutions such as Economic Daily and CCTV.

In 2024, he was invited to participate in a special interview on health industry investment for Peking University Chengze Internal Reference and engaged in the pre-research work for the "15th Five-Year Plan" for the biomanufacturing industry of the Ministry of Industry and Information Technology, providing decision-making references for national industrial policies.

In 2025, he joined hands with the Institute for Global Health Development at Peking University and the Center for Synthetic and Systems Biology at Tsinghua University to co-found the Global Health Synthetic Biology Consortium.